Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel L Aitken

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Clinical and Vaccine Immunology : CVI|January 31, 2014
Colonic immunopathogenesis of Clostridium difficile infectionsCharles Darkoh, Bradley P Turnwald, Hoonmo L Koo, et al.
The Annals of Pharmacotherapy|April 2, 2014
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnosticsSamuel L Aitken, Nicholas D Beyda, Dhara N Shah, et al.
Open Forum Infectious Diseases|February 14, 2022
Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United StatesJason N Barreto, Samuel L Aitken, Elizabeth M Krantz, et al.
The Journal of Antimicrobial Chemotherapy|November 28, 2015
Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipientsSamuel L Aitken, Jian Zhou, Shashank S Ghantoji, et al.
Antimicrobial Agents and Chemotherapy|April 27, 2022
New Perspectives on Antimicrobial Agents: Long-Acting LipoglycopeptidesTruc T Tran, Sara Gomez Villegas, Samuel L Aitken, et al.
Journal of Global Antimicrobial Resistance|February 5, 2022
In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancerKenneth V I Rolston, Bahgat Z Gerges, Ruth Reitzel, et al.
International Journal of Antimicrobial Agents|February 11, 2015
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumoniaSamuel L Aitken, Jerry Altshuler, David J Guervil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Journal of Clinical Gastroenterology|January 23, 2016
Development and Validation of a Clostridium difficile Health-related Quality-of-Life QuestionnaireKevin W Garey, Samuel L Aitken, Liliane Gschwind, et al.
Open Forum Infectious Diseases|April 24, 2023
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case SeriesMadison Breeden, Samuel L Aitken, Ji Hoon Baang, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Clinical and Vaccine Immunology : CVI|January 31, 2014
Colonic immunopathogenesis of Clostridium difficile infectionsCharles Darkoh, Bradley P Turnwald, Hoonmo L Koo, et al.
The Annals of Pharmacotherapy|April 2, 2014
Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnosticsSamuel L Aitken, Nicholas D Beyda, Dhara N Shah, et al.
Open Forum Infectious Diseases|February 14, 2022
Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United StatesJason N Barreto, Samuel L Aitken, Elizabeth M Krantz, et al.
The Journal of Antimicrobial Chemotherapy|November 28, 2015
Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipientsSamuel L Aitken, Jian Zhou, Shashank S Ghantoji, et al.
Antimicrobial Agents and Chemotherapy|April 27, 2022
New Perspectives on Antimicrobial Agents: Long-Acting LipoglycopeptidesTruc T Tran, Sara Gomez Villegas, Samuel L Aitken, et al.
Journal of Global Antimicrobial Resistance|February 5, 2022
In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancerKenneth V I Rolston, Bahgat Z Gerges, Ruth Reitzel, et al.
International Journal of Antimicrobial Agents|February 11, 2015
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumoniaSamuel L Aitken, Jerry Altshuler, David J Guervil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2025
First report of treatment-emergent resistance to cefepime-zidebactam in Pseudomonas aeruginosaAva J Dorazio, Samuel L Aitken, Virginia M Pierce, et al.
Journal of Clinical Gastroenterology|January 23, 2016
Development and Validation of a Clostridium difficile Health-related Quality-of-Life QuestionnaireKevin W Garey, Samuel L Aitken, Liliane Gschwind, et al.
Open Forum Infectious Diseases|April 24, 2023
Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case SeriesMadison Breeden, Samuel L Aitken, Ji Hoon Baang, et al.
Pageof 11